前 言
现代医学的发展将会获得越来越复杂的数据,时间和空间上高度动态的系统数据将会对诊断、治疗和预测结果提供帮助。类器官有望成为治疗各种胃肠道疾病的高价值系统,用于模拟免疫反应、代谢机制、肿瘤发生与发展、感染性消化道疾病等。截止到2023年7月中旬,全球类器官的临床研究超过170例,其中消化系统疾病的研究有70多例。为了助力类器官的培养和研究,义翘神州可提供自主研发的人源EGF、NOG、RSPO1等重组细胞因子产品。
01肠类器官研究进展
肠类器官(Intestinal organoids)从人类肠道组织或干细胞中分离和培养构建。通过在适当的培养条件下处理这些细胞,可以形成三维的肠道结构。当充分成熟时,人类肠道类器官会重现出芽的隐窝和绒毛结构域,分别含有增殖的ISC和祖细胞,以及分化的肠上皮细胞、杯状细胞和潘氏细胞。
?义翘神州细胞因子产品数据
Human RSPO1 Protein, Cat: 11083-HNAS
高纯度:
≥ 95 % as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.
高批间一致性
Induce activation of ?catenin response in a Topflash Luciferase assay using HEK293T human embryonic kidney cells.
Human Noggin Protein, Cat: 10267-HNAH
高纯度:
≥95% as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.
高批间一致性
Inhibit BMP4-induced alkaline phosphatase production by MC3T3E1 mouse preosteoblast cells.
肠类器官培养相关的细胞因子 |
货号 | 靶点 | 内毒素 | 纯度及活性 |
10605-HNAE | EGF | <5 EU/mg | ≥95%☆, Active |
GMP-10605-HNAE | EGF | <5 EU/mg | ≥95%☆, Active |
GMP-10014-HNAE | FGF2 | <10 EU/mg | ≥95%, Active |
10210-H07E | FGF7 | <0.01 EU/μg | ≥95%☆, Active |
10267-HNAH | NOG | <10 EU/mg | ≥95%☆, Active |
10007-HNAH | CSF3 | <10 EU/mg | ≥95%☆, Active |
10236-H02H | EPO | <10 EU/mg | ≥95%☆, Active |
10573-HNAE | FGF10 | <5 EU/mg | ≥95%☆, Active |
11858-HNAE | IL3 | <5 EU/mg | ≥95%☆, Active |
GMP-11858-HNAE | IL3 | <5 EU/mg | ≥95%☆, Active |
10451-HNAE | KITLG | <10 EU/mg | ≥95%☆, Active |
11066-HNAH | VEGFA | <10 EU/mg | ≥95%☆, Active |
10424-H08H | VTN | <10 EU/mg | ≥95%, Active |
10429-HNAH | INHBA | <10 EU/mg | ≥95%☆, Active |
GMP-10429-HNAH | INHBA | <10 EU/mg | ≥95%☆, Active |
10463-HNAS | HGF | <0.01 EU/μg | ≥95%☆, Active |
11083-HNAS |
RSPO1 |
<10 EU/mg | ≥95%☆, Active |
11648-H08H | JAG1 | <10 EU/mg | ≥95%☆, Active |
10452-HNAH | OSM | <10 EU/mg | ≥95%☆, Active |
GMP-10452-HNAH | OSM | <5 EU/mg | ≥95%☆, Active |
10573-HNAE | FGF10 | <5 EU/mg | ≥95%☆, Active |
GMP-10573-HNAE | FGF10 | <5 EU/mg | ≥95%☆, Active |
☆:SDS-PAGE & SEC-HPLC
【参考文献】
1. Taelman, J., Diaz, M., & Guiu, J. Human Intestinal Organoids: Promise and Challenge. Frontiers in cell and developmental biology, 2022. https://doi.org/10.3389/fcell.2022.854740
2. Kakni, P., et al. PSC-derived intestinal organoids with apical-out orientation as a tool to study nutrient uptake, drug absorption and metabolism. Frontiers in molecular biosciences, 2023. https://doi.org/10.3389/fmolb.2023.1102209
3. Rubert, J., et al. Intestinal Organoids: A Tool for Modelling Diet-Microbiome-Host Interactions. Trends in endocrinology and metabolism: TEM, 2022. https://doi.org/10.1016/j.tem.2020.02.004
4. Günther, C., et al. Organoids in gastrointestinal diseases: from experimental models to clinical translation. Gut, 2022. https://doi.org/10.1136/gutjnl-2021-326560
5. Wang, Q., et al. Applications of human organoids in the personalized treatment for digestive diseases. Signal transduction and targeted therapy, 2022. https://doi.org/10.1038/s41392-022-01194-6
6. Abud, H. E., et al. Source and Impact of the EGF Family of Ligands on Intestinal Stem Cells. Frontiers in cell and developmental biology, 2021. https://doi.org/10.3389/fcell.2021.685665
7. Krause, C., Guzman, A., & Knaus, P. Noggin. The international journal of biochemistry & cell biology, 2011.
https://doi.org/10.1016/j.biocel.2011.01.007
8. Li, Y., et al. Bach2 Deficiency Promotes Intestinal Epithelial Regeneration by Accelerating DNA Repair in Intestinal Stem Cells. Stem cell reports, 2021. https://doi.org/10.1016/j.stemcr.2020.12.005
9. Chen, L., et al. Molecular Biomarker of Drug Resistance Developed From Patient-Derived Organoids Predicts Survival of Colorectal Cancer Patients. Frontiers in oncology, 2022. https://doi.org/10.3389/fonc.2022.855674
10. Tang, M., et al. Evaluation of B7-H3 Targeted Immunotherapy in a 3D Organoid Model of Craniopharyngioma. Biomolecules, 2022. https://doi.org/10.3390/biom12121744
11. Ruan, D., et al. Human early syncytiotrophoblasts are highly susceptible to SARS-CoV-2 infection. Cell reports. Medicine, 2022. https://doi.org/10.1016/j.xcrm.2022.100849